Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzony guz lity, miejscowo zaawansowany lub z przerzutami, oporny na dostępne leczenie
- •Lub rak piersi potrójnie ujemny/drobnokomórkowy rak płuca/guz lity z określonymi zmianami genetycznymi (RB1, CDKN2A/B)
- •Mierzalna choroba
- •Wiek od 18 lat
- •Dobry stan sprawności (ECOG 0-1)
- •Oczekiwane przeżycie >12 tygodni
- •Możliwość pobrania świeżej biopsji
- •Zdolność połykania kapsułek
- •Prawidłowa funkcja nerek, wątroby i krwi
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Years
- Last updated (source)
- September 15, 2025
- Sex
- No restrictions
Therapies / drugs in trial
Locations (10)
Florida Cancer Specialists
Sarasota, United States
Dana Farber Cancer Institute
Boston, United States
START Midwest
Grand Rapids, United States
Comprehensive Cancer Centers of Nevada
Las Vegas, United States
UH Seidman Cancer Center
Cleveland, United States
Oregon Health and Science University
Portland, United States
Sarah Cannon Research Institute
Nashville, United States
MD Anderson Cancer Center
Houston, United States
NEXT Oncology
San Antonio, United States
START Mountain
West Valley City, United States
Trial contact
Lisa Kopp, DO, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.